Live tape
Top 8, mentions 7d18,255MSFT3,395 mentions▲ +0.09AAPL2,656 mentions▲ +0.07GOOGL2,632 mentions▲ +0.05META2,225 mentions▲ +0.04SNDK2,157 mentions▲ +0.06NVDA1,838 mentions▲ +0.07SPCX1,707 mentions▲ +0.06AMZN1,645 mentions▲ +0.10

Equity · Healthcare

MEDP

Medpace Holdings, Inc. · NasdaqGS

$538.00 +0.01% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart Chart by TradingView
Track this symbol on TradingView

The chart above plots the price of MEDP over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 54 sessions over that window: $417.00 on 4 May 2026 through $538.00 on 17 July 2026. Finazon · prior-day close.

Market cap $15.0B
P/E (TTM) 34.7
52-week range $312.00 – $630.00
Avg volume 77.0K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 2, 2026

MEDP insider trades

SEC Form 4 · last 90 days · newest reported trade 28 Jul 2026
Open-market buys 0
Open-market sells 4
Net sold $16.20M
Non-trade filings 4
Date Insider Type Shares Value
28 Jul 2026 BURWIG SUSAN E Exec. VP, Operations Sell 7,500 $4.50M
28 Jul 2026 Troendle August J. President & CEO Sell 3,510 $2.11M
27 Jul 2026 Troendle August J. President & CEO Sell 3,728 $2.24M
28 May 2026 EWALD STEPHEN P General Counsel & Corp. Secy. Sell 16,349 $7.36M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
30 Jun 2026 Carley Brian T Director Option exercise 36
30 Jun 2026 Kraft Robert O. Director Option exercise 33
30 Jun 2026 McCarthy Cornelius P. III Director Option exercise 28
28 May 2026 EWALD STEPHEN P General Counsel & Corp. Secy. Option exercise 16,349 $2.27M

MEDP reported financials

SEC EDGAR XBRL

MEDP reported revenue of $2.5B for the fiscal year ended 31 Dec 2025. Net income over the same period was $451.1M.

Figure Reported Period
Revenue $2.5B 31 Dec 2025 fiscal year
Net income $451.1M 31 Dec 2025 fiscal year
Diluted EPS $15.28 31 Dec 2025 fiscal year
Total assets $2.1B 30 Jun 2026 at period end
Total equity $433.9M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

MEDP earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $4.25 —
31 Mar 2026 Q1 2026 $4.28 —
31 Dec 2025 FY 2025 $15.28 —
30 Sep 2025 Q3 2025 $3.86 —
30 Jun 2025 Q2 2025 $3.10 —
31 Mar 2025 Q1 2025 $3.67 —
31 Dec 2024 FY 2024 $12.63 —
30 Sep 2024 Q3 2024 $3.01 —

Reported figures & scheduled dates · SEC EDGAR filings

MEDP institutional holders

SEC Form 13F

13 of the 45 institutional funds we track reported a MEDP position for the quarter ended 31 Mar 2026 — a combined $1.3B; the latest of those filings landed 15 May 2026.

Fund Action Shares Value
AQR Capital Management Held (±25%) +0.3% shares 1,353,837 $633.6M
Renaissance Technologies Held (±25%) +8.3% shares 504,668 $242.3M
D. E. Shaw & Co. Held (±25%) −18.1% shares 432,602 $207.7M
Two Sigma Investments Added +207.7% shares 176,557 $84.8M
Fisher Asset Management Held (±25%) −2.2% shares 135,712 $65.2M
Man Group Held (±25%) −13.7% shares 68,272 $32.8M
Fundsmith Held (±25%) −24.1% shares 62,668 $30.1M
Balyasny Asset Management New position 42,293 $20.3M
Bridgewater Associates Held (±25%) +19.9% shares 41,135 $19.8M
Marshall Wace Trimmed −78.1% shares 9,853 $4.7M

Source: SEC EDGAR 13F filings

MEDP fails-to-deliver

SEC CNS data

On 14 Jul 2026, 16 shares of MEDP failed to deliver (about $8K) — the latest of 2 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
14 Jul 2026 16 $8K <0.001%
13 Jul 2026 15 $8K <0.001%
06 Jul 2026 2,867 $1.6M 0.010%
02 Jul 2026 400 $217K 0.001%
30 Jun 2026 1,190 $636K 0.004%
29 Jun 2026 3 $2K <0.001%
22 Jun 2026 2,136 $983K 0.008%

Source: SEC fails-to-deliver (CNS) data